Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.

Acute lymphoblastic leukemia has a good outlook or prognosis in children but a poorer outlook in adults. Infant variety of ALL however has a poor prognosis. There are some common factors that ...

People with the subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) associated with fusion of MEF2D with other genes show quite poor prognosis. Most patients fail to respond to ...

Overall, 771 patients achieved CR (84%). Median disease-free survival (DFS) was 17.5 months, with 3-year DFS at 37%. In group 1, the 3-year DFS rate was 41%, with no difference between arms of ...

Chemotherapy-free regimens in Philadelphia chromosome–positive acute lymphoblastic leukemia and optimization of combination therapies are among advances from ASH 2023 chosen by Dr Hagop Kantarjian.

Acute lymphoblastic leukemia (ALL) represents around 70% of pediatric leukemia. In high-income countries, the 5-year survival is above 90%, but survival in low- and middle-income countries is inferior ...